SMA Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

SMA Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-262	Closed	-$6.49K	–	135
2026 Q1	$6.49K	Buy	+262	New	+$6.24K	﹤0.01%	72

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SMA Capital's CPRX Position: Q2 2026 in Review

SMA Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 262 shares — an estimated $6.49K sold.

SMA Capital first reported a position in CPRX in Q1 2026 and held it in 1 quarter. The position peaked at $6.49K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

SMA Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 262 Catalyst Pharmaceutical shares in Q2 2026, an estimated $6.49K.
SMA Capital first reported a position in Catalyst Pharmaceutical in Q1 2026 and held it in 1 quarter.
SMA Capital's Catalyst Pharmaceutical position peaked at $6.49K in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.